Drug intelligence / Profile preview

haemophilus influenzae type b conjugate vaccine + meningococcal serogroups C and Y tetanus toxoid conjugate vaccine

Development stage
Unknown
Lead developer
GSK
Modality
Vaccines & Immunotherapeutics
Administration
Intramuscular
01

Overview

This is a **combination vaccine** comprised of two conjugate vaccines: - **Haemophilus influenzae type b (Hib) conjugate vaccine (tetanus toxoid conjugate)**: Induces immunity against invasive disease caused by *Haemophilus influenzae* type b, a significant cause of childhood morbidity and mortality including meningitis, pneumonia, epiglottitis, and septic arthritis. The mechanism is based on induction of antigen-specific immune responses to the PRP (polyribosylribitol phosphate) capsule of Hib, facilitated by conjugation to tetanus toxoid, which enables T-cell dependent immunogenicity and long-lasting protection[1][2][3][4][5][6]. - **Meningococcal conjugate vaccine (serogroups C and Y, tetanus toxoid conjugate)**: Induces immunity to *Neisseria meningitidis* serogroups C and Y, which can cause bacterial meningitis and septicemia. This component similarly uses capsular polysaccharides from the relevant serogroups conjugated to tetanus toxoid, stimulating T-cell dependent immune responses and generation of immunological memory. The combined formulation is designed to protect against invasive diseases caused by both Hib and *N. meningitidis* serogroups C and Y in pediatric populations.

02

Targets

Neisseria meningitidis group C capsular polysaccharideGroup Y CPS (Neisseria meningitidis group Y capsular polysaccharide)

Beyond the preview

Go deeper on haemophilus influenzae type b conjugate vaccine + meningococcal serogroups C and Y tetanus toxoid conjugate vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on haemophilus influenzae type b conjugate vaccine + meningococcal serogroups C and Y tetanus toxoid conjugate vaccine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call